Marshall Wace’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Marshall Wace’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$919K	Buy	392,643 +144,855	+58%	+$374K	﹤0.01%	2178
2025 Q4	$335K	Buy	+247,788	New	+$361K	﹤0.01%	2409
2025 Q1	–	Sell	-89,012	Closed	-$270K	–	3163
2024 Q4	$270K	Hold	89,012	–	–	﹤0.01%	2268
2024 Q3	$328K	Hold	89,012	–	–	﹤0.01%	2097
2024 Q2	$364K	Hold	89,012	–	–	﹤0.01%	2083
2024 Q1	$1.4M	Hold	89,012	–	–	﹤0.01%	1519
2023 Q4	$1.35M	Sell	89,012 -181,826	-67%	-$2.65M	﹤0.01%	1371
2023 Q3	$5.43M	Sell	270,838 -245,207	-48%	-$6.22M	0.01%	843
2023 Q2	$14.6M	Buy	+516,045	New	+$12.4M	0.03%	596

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Marshall Wace's ZNTL Position: Q1 2026 in Review

Marshall Wace increased its Zentalis Pharmaceuticals (ZNTL) stake by 58% in Q1 2026, buying an estimated $374K and bringing the position to 392,643 shares worth $919K. The position accounts for ﹤0.01% of the portfolio, ranked #2178.

Marshall Wace first reported a position in ZNTL in Q2 2023 and has held it in 9 quarters since. The position peaked at $14.6M in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Marshall Wace held 392,643 shares of Zentalis Pharmaceuticals worth $919K as of Q1 2026.
Marshall Wace bought 144,855 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $374K.
Zentalis Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2178 holding.
Marshall Wace first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
Marshall Wace's Zentalis Pharmaceuticals position peaked at $14.6M in Q2 2023.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.